Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002595554 | SCV003495335 | uncertain significance | not provided | 2022-06-25 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 300 of the PRDM5 protein (p.Cys300Arg). This variant is present in population databases (rs777726075, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with PRDM5-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV003147825 | SCV003835970 | uncertain significance | Brittle cornea syndrome 2 | 2022-11-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003161897 | SCV003913015 | uncertain significance | Cardiovascular phenotype | 2023-02-23 | criteria provided, single submitter | clinical testing | The p.C300R variant (also known as c.898T>C), located in coding exon 8 of the PRDM5 gene, results from a T to C substitution at nucleotide position 898. The cysteine at codon 300 is replaced by arginine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |